 DARTMOUTH, Nova Scotia--BUSINESS WIRE--IMV Inc. Nasdaq: IMV; TSX: IMV, a clinical-stage biopharmaceutical company pioneering a novel class of cancer immunotherapies and vaccines against infectious diseases, today announced that the Company will host a key opinion leader KOL webcast on the treatment options in ovarian cancer and competitive landscape within the disease state on Thursday, December 3, 2020 at 8.00am Eastern Time. The webcast will feature presentations by KOLs Oliver Dorigo, 